{{Drugbox
| Watchedfields = changed
| verifiedrevid =
| IUPAC_name = 5-[(1''R'')-2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}- 1-hydroxyethyl]-8-hydroxyquinolin-2(1''H'')-one
| image = Abediterol.svg
| width = 225

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only  / Schedule I, II, III, IV, V -->
| routes_of_administration = Inhalation
| legal_status = Experimental

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life = 24.3 hours<ref>{{cite journal|last1=Timmer|first1=Wolfgang|last2=Massana|first2=Eric|last3=Jimenez|first3=Eulalia|last4=Seoane|first4=Beatriz|last5=de Miquel|first5=Gonzalo|last6=Ruiz|first6=Sandrine|title=First-in-Human Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Abediterol (LAS100977), a Novel Long-Acting β<sub>2</sub>-agonist|journal=The Journal of Clinical Pharmacology|date=December 2014|volume=54|issue=12|pages=1347–53|doi=10.1002/jcph.355}}</ref>
| excretion =  

<!--Identifiers-->
| CAS_number = 915133-65-2
| ATC_prefix = None
| ATC_suffix =  
| PubChem = 11962616
| IUPHAR_ligand =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10136846
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = QXA167CM6F
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D10219
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 3039530

<!--Chemical data-->
| C=25 | H=30 | F=2 | N=2 | O=4
| molecular_weight = 403.898 g/mol
| smiles = FC(F)(c1ccccc1)COCCCCCCNC[C@H](O)c3ccc(O)c2c3\C=C/C(=O)N2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SFYAXIFVXBKRPK-QFIPXVFZSA-N
}}<!--|accessdate=25 March 2016-->

'''Abediterol''' ([[International Nonproprietary Name|INN]])<ref>{{cite journal|title=International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 104|journal=WHO Drug Information|date=2010|volume=24|issue=1|page=352|url=http://www.who.int/medicines/publications/druginformation/issues/PL-104.pdf|accessdate=25 March 2016}}</ref> (codenamed AZD-0548, LAS 100977) is a novel, once-daily experimental drug candidate for the treatment of [[asthma]] and [[chronic obstructive pulmonary disease]] (COPD). It is currently under [[drug development|development]] by the Spanish pharmaceutical company [[Almirall]] and is in [[Phases of clinical research#Phase II|Phase II]] clinical trials.<ref>[http://www.almirall.com/webcorp2/cda/ImD_03_02.jsp Product development pipeline], [[Almirall]]</ref><ref>{{cite web|title=AdisInsight: Abediterol|url=http://adisinsight.springer.com/drugs/800026746|website=Adis Insight|publisher=Springer International Publishing AG|accessdate=25 March 2016}}</ref>

It acts as a dual [[Beta2-adrenergic agonist|β<sub>2</sub> adrenergic agonist]]<ref>{{cite patent|WO|2006122788}}</ref><ref>{{cite patent|WO|2010094484}}</ref> and [[muscarinic antagonist]] and is classified as an [[Long-acting beta-adrenoceptor agonist|ultra-long-acting β<sub>2</sub> agonist]] (ultra-LABA).<ref>{{cite journal|last1=Beier|first1=J|last2=Fuhr|first2=R|last3=Massana|first3=E|last4=Jiménez|first4=E|last5=Seoane|first5=B|last6=de Miquel|first6=G|last7=Ruiz|first7=S|title=Abediterol (LAS100977), a novel long-acting β<sub>2</sub>-agonist: Efficacy, safety and tolerability in persistent asthma|journal=Respiratory Medicine|date=October 2014|volume=108|issue=10|pages=1424–1429|doi=10.1016/j.rmed.2014.08.005|pmid=25256258|url=http://www.resmedjournal.com/article/S0954-6111(14)00287-X/pdf|accessdate=25 March 2016}}</ref>

Its coformulation with [[mometasone furoate]] is also in Phase II clinical trials.<ref>{{cite web|title=AdisInsight: Abediterol/mometasone|url=http://adisinsight.springer.com/drugs/800033847|website=Adis Insight|publisher=Springer International Publishing AG|accessdate=25 March 2016}}</ref>

==References==
{{reflist|2}}

{{Asthma and copd rx}}
{{Adrenergic receptor modulators}}
{{Muscarinic acetylcholine receptor modulators}}

[[Category:Long-acting beta2-adrenergic agonists]]
[[Category:Muscarinic antagonists]]
[[Category:Organofluorides]]
[[Category:2-Quinolones]]


{{respiratory-system-drug-stub}}